A Phase 3 interventional study of Nilotinib in Chronic Myeloid Leukemia, sponsored by Novartis Pharmaceuticals. Completed at 100 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-03-03.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive — 2 open to participants now, 3 under way, none of them phase 3. nilotinib · Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, this one is the 5th largest by enrollment, is one of 4 that started in 2011, is one of 15 in phase 3, and was the 24th registered.
894 studies on the registry are indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive; 109 are open to participants now.
Browse Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies →2 of the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive are open now, in 12 countries. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in United States, Argentina, Austria and 26 more countries
Ages 7–100
Medical College of Wisconsin · Sites in United States
Ages 18+
By country, each count listing its studies:
nilotinib: first FDA approval 2007 (TASIGNA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 79 Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies recruiting now, 48 (61%) set no upper age limit and 20 (25%) stop at 75 or younger; 20 take children under 18; 7 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
66 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 12 · Phase 2 32 · Phase 3 16 · Phase 4 12
First in 2001; this study’s year is marked. 4 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 421 is above the median of 44 across 681 interventional studies indexed under Leukemia, Myelogenous, Chronic, BCR-ABL Positive.
Median enrollment 55 across the 66 interventional studies. Of the 54 that completed or were terminated, 29 (54%) have results posted.
This tab as a report to print or save as PDF → With an account.
35 of 66 have an industry lead sponsor. The 10 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis: 9 open now, 13 under way, 2 of them phase 3. Of 73 finished, 35 (48%) have results posted.
Among the 92 studies in Leukemia, Myelogenous, Chronic, BCR-ABL Positive by Novartis, this one is the 8th largest by enrollment of the 63 interventional ones that give a count, is one of 4 that started in 2011, is one of 19 in phase 3, and was the 39th registered.
Novartis’s Leukemia, Myelogenous, Chronic, BCR-ABL Positive studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 66 studies testing nilotinib in Leukemia, Myelogenous, Chronic, BCR-ABL Positive, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 92 in Leukemia, Myelogenous, Chronic, BCR-ABL Positive:
This tab as a report to print or save as PDF → With an account.
This study will further investigate the safety and efficacy of nilotinib in newly diagnosed chronic myeloid leukemia patients in the chronic phase
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
-Patients with chronic myeloid leukemia in the chronic phase diagnosed within 6 months of study entry
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
300 mg BID
Drug: Nilotinib
This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
Also known as: AMN107
The Percentage of Patients Achieving MMR by 12 Months
MMR is defined as BCR-ABL ratio (%) on IS \<= 0.1% (corresponds to \>=3 log reduction of BCR-ABL transcripts from standardized baseline value). Clopper-Pearson method
Time frame: 12 months
Time to Molecular Response at 24 Months
Estimated median time to first MMR by Kaplan-Meier method
Time frame: 24 months
Duration of Major Molecular Response
Kaplan-Meier estimates of duration of first MMR among patients who achieved MMR (FAS) Duration of first MMR (months) = (Minimum date of (loss of first MMR , CML-related death, progression to AP/BC during study treatment, censoring) - date of first MMR + 1) / 30.4375
Time frame: 3, 6, 9, 12, 15, 18, 21, 24 Months after MMR was detected
Complete Cytogenetic Response
Complete cytogenetic response (CCyR) is defined as a value of 0% Ph+ metaphases in bone marrow.
Time frame: 6 months
Percentage of Participants Estimated to Maintain Their First CCyR for 6, 12, 18, and 24 Months After the First CCyR Was Achieved as Determined by Kaplan Meier Estimatation.
\* CCyR = 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Duration of first CCyR (months) = (date of CCyR loss or censoring - date of first CCyR +1) / 30.4375
Time frame: 6,12,18 and 24 months
Overall Survival
OS was defined as the time between date of study entry and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.
Time frame: 3, 6, 9, 12, 15, 18, 21, 24 Months
Kaplan-Meier Estimates of Progression-free Survival
PFS was defined as the time from the date of study entry to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring on treatment.
Time frame: 3,6,9,12,15,18,21,and 24 months
Kaplan-Meier Estimates of Failure-free Survival
Time to event (months) = (date of event or censoring - date of study entry + 1) / 30.4375. Date of event is the earliest date of the following events during treatment : discontinuation of nilotinib for nilotinib-related adverse events, death due to any cause, progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR. Time is censored at the date of last assessment in the trial for patients without event.
Time frame: 3,6,9,12,15,18,21,and 24 months
| Milestone | Nilotinib |
|---|---|
| Started | 421 |
| Completed | 328 |
| Not completed | 93 |
| Withdrew: Disease progression | 6 |
| Withdrew: Protocol violation | 6 |
| Withdrew: Pregnancy | 2 |
| Withdrew: Death | 4 |
| Withdrew: Lost to follow-up | 5 |
| Withdrew: Withdrawal by subject | 7 |
| Withdrew: Adverse event | 43 |
| Withdrew: Per investigator discretion | 20 |
MMR is defined as BCR-ABL ratio (%) on IS \<= 0.1% (corresponds to \>=3 log reduction of BCR-ABL transcripts from standardized baseline value). Clopper-Pearson method
| percentage of participants | Nilotinib |
|---|---|
| The Percentage of Patients Achieving MMR by 12 Months | 70.8 (66.1 to 75.2) |
Estimated median time to first MMR by Kaplan-Meier method
| Months | Nilotinib |
|---|---|
| Time to Molecular Response at 24 Months | 6.0 (5.9 to 6.1) |
Kaplan-Meier estimates of duration of first MMR among patients who achieved MMR (FAS) Duration of first MMR (months) = (Minimum date of (loss of first MMR , CML-related death, progression to AP/BC during study treatment, censoring) - date of first MMR + 1) / 30.4375
| percentage of participants | Nilotinib |
|---|---|
| K-M Estimate for 3 Month Duration | 100 (100 to 100) |
| K-M Estimate for 6 Month Duration | 97.1 (65.2 to 99.0) |
| K-M Estimate for 9 Month Duration | 92.8 (89.9 to 95.7) |
| K-M Estimate for 12 Month Duration | 92.1 (89.1 to 95.1) |
| K-M Estimate for 15 Month Duration | 91.7 (88.5 to 94.8) |
| 18 months | 90.8 (87.4 to 94.1) |
| K-M Estimate for 21 Month Duration | 89.7 (85.7 to 93.6) |
| K-M Estimate for 24 Month Duration | 85.2 (75.8 to 94.5) |
Complete cytogenetic response (CCyR) is defined as a value of 0% Ph+ metaphases in bone marrow.
| percentage of participants | Nilotinib |
|---|---|
| Complete Cytogenetic Response | 58.7 (53.8 to 63.4) |
\* CCyR = 0% Ph+ metaphases based on at least 20 metaphases from bone marrow cytogenetics. Duration of first CCyR (months) = (date of CCyR loss or censoring - date of first CCyR +1) / 30.4375
| percentage of participants | Nilotinib |
|---|---|
| 6 mos after the first CCyR was achieved | 100 (100 to 100) |
| 12 mos after the first CCyR was achieved | 99.6 (98.8 to 100) |
| 18 mos after the first CCyR was achieved | 98.7 (97.1 to 100) |
| 24 mos after the first CCyR was achieved | 98.7 (97.1 to 100) |
OS was defined as the time between date of study entry and date of death due to any cause at any time during the study, including the follow-up period after discontinuation of treatment.
| percentage probability | Nilotinib |
|---|---|
| 3 months K-M Estimate | 99.8 (99.3 to 100) |
| 6 months K-M Estimate | 99.5 (98.9 to 100) |
| 9 months K-M Estimate | 99.5 (98.9 to 100) |
| 12 months K-M Estimate | 99.0 (98.0 to 100) |
| 15 months K-M Estimate | 98.2 (96.9 to 99.5) |
| 18 months K-M Estimate | 97.6 (96.1 to 99.2) |
| 21 months K-M Estimate | 97.6 (96.1 to 99.2) |
| 24 months K-M Estimate | 97.6 (96.1 to 99.2) |
PFS was defined as the time from the date of study entry to the date of event defined as the first documented disease progression to AP/BC or the date of death from any cause occurring on treatment.
| percentage probability | Nilotinib |
|---|---|
| 3 mos | 99.7 (99.3 to 100) |
| 6 mos | 99.5 (98.8 to 100) |
| 9 mos | 98.9 (97.8 to 100) |
| 12 mos | 98.6 (97.4 to 99.8) |
| 15 mos | 98.0 (96.5 to 99.5) |
| 18 mos | 97.6 (96.0 to 99.3) |
| 21 mos | 97.6 (96.0 to 99.3) |
| 24 mos | 97.0 (95.1 to 98.8) |
Time to event (months) = (date of event or censoring - date of study entry + 1) / 30.4375. Date of event is the earliest date of the following events during treatment : discontinuation of nilotinib for nilotinib-related adverse events, death due to any cause, progression to AP or BC, loss of PCyR, loss of CCyR, loss of CHR. Time is censored at the date of last assessment in the trial for patients without event.
| percentage probability | Nilotinib |
|---|---|
| 3 mos | 97.4 (95.8 to 98.9) |
| 6 mos | 95.9 (93.9 to 97.8) |
| 9 mos | 94.6 (92.4 to 96.8) |
| 12 mos | 93.6 (91.2 to 96.0) |
| 15 mos | 92.0 (89.4 to 94.7) |
| 18 mos | 91.0 (88.2 to 93.8) |
| 21 mos | 89.7 (86.6 to 92.7) |
| 24 mos | 88.8 (85.7 to 92.0) |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Nilotinib | — | 97/421 (23%) | 357/421 (84.8%) |
| Event | Nilotinib |
|---|---|
| THROMBOCYTOPENIABlood and lymphatic system disorders | 12/421 |
| PANCREATITISGastrointestinal disorders | 7/421 |
| ANAEMIABlood and lymphatic system disorders | 4/421 |
| FEBRILE NEUTROPENIABlood and lymphatic system disorders | 4/421 |
| ATRIAL FIBRILLATIONCardiac disorders | 4/421 |
| PNEUMONIAInfections and infestations | 4/421 |
| NEUTROPENIABlood and lymphatic system disorders | 3/421 |
| ANGINA UNSTABLECardiac disorders | 3/421 |
| PYREXIAGeneral disorders | 3/421 |
| BLAST CELL CRISISNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/421 |
| Event | Nilotinib |
|---|---|
| THROMBOCYTOPENIABlood and lymphatic system disorders | 78/421 |
| HEADACHENervous system disorders | 77/421 |
| RASHSkin and subcutaneous tissue disorders | 76/421 |
| LIPASE INCREASEDInvestigations | 66/421 |
| NAUSEAGastrointestinal disorders | 60/421 |
| CONSTIPATIONGastrointestinal disorders | 51/421 |
| ALANINE AMINOTRANSFERASE INCREASEDInvestigations | 51/421 |
| ALOPECIASkin and subcutaneous tissue disorders | 50/421 |
| PRURITUSSkin and subcutaneous tissue disorders | 50/421 |
| FATIGUEGeneral disorders | 48/421 |
Newly diagnosed CML-CP patients not previously treated with imatinib and diagnosed within 6 months of study entry, except for hydroxyurea, and/or anagrelide . In emergent cases where the patient requires disease management Gleevec/Glivec at any dose may be prescribed to the patient for no longer than 2 weeks in duration
| Age, Categorical(Participants) | Nilotinib |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 368 |
| >=65 years | 53 |
| Age, Continuous(years) | Nilotinib |
|---|---|
| Mean | 47.13 ± 14.892 |
| Sex: Female, Male(Participants) | Nilotinib |
|---|---|
| Female | 195 |
| Male | 226 |
The record gives a start of Apr 2011, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2016, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nilotinib
Leukemia, Myelogenous, Chronic, BCR-ABL Positive →